Catherine Klein
Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Topotecan | 1 | 2002 | 13 | 0.220 |
Why?
| Antineoplastic Agents | 4 | 2014 | 1974 | 0.180 |
Why?
| Fanconi Anemia Complementation Group N Protein | 1 | 2017 | 5 | 0.150 |
Why?
| Breast Neoplasms, Male | 1 | 2017 | 31 | 0.150 |
Why?
| Breast Neoplasms | 3 | 2014 | 1965 | 0.140 |
Why?
| Prostatic Neoplasms | 1 | 2002 | 940 | 0.130 |
Why?
| Mutation | 2 | 2017 | 3457 | 0.130 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2014 | 91 | 0.120 |
Why?
| Multiple Myeloma | 1 | 2015 | 100 | 0.120 |
Why?
| Carcinoma in Situ | 1 | 2011 | 45 | 0.100 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2014 | 455 | 0.100 |
Why?
| Carcinoma, Lobular | 1 | 2011 | 56 | 0.090 |
Why?
| Tocopherols | 1 | 2009 | 20 | 0.090 |
Why?
| Isotretinoin | 1 | 2009 | 22 | 0.090 |
Why?
| BRCA2 Protein | 1 | 2009 | 44 | 0.090 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2009 | 51 | 0.090 |
Why?
| Thrombophilia | 1 | 2009 | 68 | 0.080 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1390 | 0.080 |
Why?
| Pyrazines | 2 | 2015 | 72 | 0.080 |
Why?
| Veterans | 1 | 2015 | 1208 | 0.060 |
Why?
| Aged, 80 and over | 4 | 2015 | 6561 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2002 | 380 | 0.050 |
Why?
| Survival Analysis | 1 | 2002 | 1267 | 0.040 |
Why?
| Drug Resistance, Neoplasm | 1 | 2002 | 671 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2009 | 2220 | 0.030 |
Why?
| Aged | 4 | 2015 | 19657 | 0.030 |
Why?
| Adult | 6 | 2017 | 31512 | 0.030 |
Why?
| Melanoma | 1 | 2002 | 664 | 0.030 |
Why?
| Bortezomib | 1 | 2015 | 42 | 0.030 |
Why?
| Boronic Acids | 1 | 2015 | 35 | 0.030 |
Why?
| Autografts | 1 | 2015 | 49 | 0.030 |
Why?
| Prognosis | 2 | 2014 | 3443 | 0.030 |
Why?
| Mastectomy | 1 | 2014 | 124 | 0.030 |
Why?
| Stem Cell Transplantation | 1 | 2015 | 153 | 0.030 |
Why?
| Male | 6 | 2017 | 57801 | 0.030 |
Why?
| Lymphatic Metastasis | 1 | 2014 | 307 | 0.030 |
Why?
| Middle Aged | 4 | 2015 | 27617 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2015 | 649 | 0.030 |
Why?
| Dexamethasone | 1 | 2015 | 320 | 0.030 |
Why?
| Humans | 8 | 2017 | 118972 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2014 | 1166 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2011 | 190 | 0.020 |
Why?
| Survival Rate | 1 | 2015 | 1720 | 0.020 |
Why?
| Disease Management | 1 | 2014 | 571 | 0.020 |
Why?
| Female | 6 | 2015 | 61564 | 0.020 |
Why?
| Pregnancy Trimester, Second | 1 | 2009 | 70 | 0.020 |
Why?
| Mastectomy, Segmental | 1 | 2009 | 91 | 0.020 |
Why?
| Cyclophosphamide | 1 | 2009 | 222 | 0.020 |
Why?
| Pregnancy Trimester, First | 1 | 2009 | 126 | 0.020 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2009 | 190 | 0.020 |
Why?
| Lymph Node Excision | 1 | 2009 | 158 | 0.020 |
Why?
| Treatment Outcome | 1 | 2002 | 9342 | 0.020 |
Why?
| Doxorubicin | 1 | 2009 | 302 | 0.020 |
Why?
| Bronchoscopy | 1 | 2009 | 247 | 0.020 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 900 | 0.010 |
Why?
| Injections, Intravenous | 1 | 2002 | 210 | 0.010 |
Why?
| Smoking | 1 | 2009 | 1487 | 0.010 |
Why?
| Young Adult | 1 | 2014 | 10793 | 0.010 |
Why?
| Infant, Newborn | 1 | 2009 | 5255 | 0.010 |
Why?
| Pregnancy | 1 | 2009 | 5690 | 0.010 |
Why?
| Lung | 1 | 2009 | 3664 | 0.010 |
Why?
| Risk Factors | 1 | 2009 | 9000 | 0.010 |
Why?
|
|
Klein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|